Skip to main content

Advertisement

SpringerLink
Log in

Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Beta-blockers (BB) drugs have been used for decades worldwide, mainly to treat hypertension. However, in recent epidemiological studies, BBs were suggested to improve cancer prognosis. In the wake of this evidence, we evaluated the possible therapeutic effect of BBs in triple-negative breast cancer (TNBC) patients. We identified 800 postmenopausal women operated between 1997 and 2008 for early primary TNBC. The effect of BB intake on the risk of breast cancer (BC) recurrence and death was evaluated through competing risk and Cox regression survival models. At cancer diagnosis, 74 (9.3 %) women out of 800 were BBs users. Median age was 62 years in BB users and 59 years in non-users (P = 0.02). BB users and non-users were similarly distributed by all tumor characteristics. The 5-year cumulative incidence of BC-related events was 13.6 % in BB users and 27.9 % in non-users (P = 0.02). The beneficial impact of BBs remained statistically significant at multivariable analysis (HR, 0.52; 95 % CI 0.28–0.97), after the adjustment for age, tumor stage, and treatment, peritumoral vascular invasion and use of other antihypertensive drugs, antithrombotics, and statins. Adjusted HRs for metastases and for BC deaths were 0.32 (95 % CI 0.12–0.90) and 0.42 (95 % CI 0.18–0.97), respectively, in favor of BBs. Hypertension, other antihypertensive drugs, antithrombotics, and statins did not impact prognosis. In this series of postmenopausal TNBC patients, BB intake was associated with a significantly decreased risk of BC-related recurrence, metastasis, and BC death. Innovative therapeutic strategies including BBs should be urgently explored in cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ram CV (2010) Beta-blockers in hypertension. Am J Cardiol 106(12):1819–1825

    Article  PubMed  CAS  Google Scholar 

  2. Grytli HH, Fagerland MW, Fosså SD et al (2013) Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol 64(1):e11–e12

    Article  PubMed  Google Scholar 

  3. Grytli HH, Fagerland MW, Fosså SD et al (2013) Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate 73(3):250–260

    Article  PubMed  CAS  Google Scholar 

  4. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X et al (2011) Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29(19):2645–2652

    Article  PubMed  CAS  Google Scholar 

  5. Barron TI, Connolly RM, Sharp L et al (2011) Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol 29(19):2635–2644

    Article  PubMed  CAS  Google Scholar 

  6. Powe DG, Voss MJ, Zänker KS et al (2010) Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1(7):628–638

    PubMed  Google Scholar 

  7. Ganz PA, Habel LA, Weltzien EK et al (2011) Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat 129(2):549–556

    Article  PubMed  CAS  Google Scholar 

  8. Wang HM, Liao ZX, Komaki R et al (2013) Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol 24(5):1312–1319

    Article  PubMed  CAS  Google Scholar 

  9. Diaz ES, Karlan BY, Li AJ (2012) Impact of beta blockers on epithelial ovarian cancer survival. Gynecol Oncol 127(2):375–378

    Article  PubMed  CAS  Google Scholar 

  10. De Giorgi V, Grazzini M, Gandini S et al (2011) Treatment with β-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med 171(8):779–781

    Article  PubMed  Google Scholar 

  11. Lemeshow S, Sørensen HT, Phillips G et al (2011) β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 20(10):2273–2279

    Article  PubMed  CAS  Google Scholar 

  12. Monami M, Filippi L, Ungar A et al (2013) Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials. Curr Med Res Opin 29(4):369–378

    Article  PubMed  CAS  Google Scholar 

  13. Perron L, Bairati I, Harel F et al (2004) Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 15(6):535–541

    Article  PubMed  Google Scholar 

  14. Powe DG, Entschladen F (2011) Targeted therapies: using β-blockers to inhibit breast cancer progression. Nat Rev Clin Oncol 8(9):511–512

    Article  PubMed  Google Scholar 

  15. Antoni MH, Lutgendorf SK, Cole SW et al (2006) The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer 6(3):240–248

    Article  PubMed  CAS  Google Scholar 

  16. Cole SW, Sood AK (2012) Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 18(5):1201–1206

    Article  PubMed  CAS  Google Scholar 

  17. Schuller HM (2010) Beta-adrenergic signaling, a novel target for cancer therapy? Oncotarget 1(7):466–469

    PubMed  Google Scholar 

  18. Campbell JP, Karolak MR, Ma Y et al (2012) Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol 10(7):e1001363

    Article  PubMed  CAS  Google Scholar 

  19. Benish M, Bartal I, Goldfarb Y et al (2008) Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol 15(7):2042–2052

    Article  PubMed  Google Scholar 

  20. Drell TL 4th, Joseph J, Lang K et al (2003) Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 80(1):63–70

    Article  PubMed  CAS  Google Scholar 

  21. Sloan EK, Priceman SJ, Cox BF et al (2010) The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 70(18):7042–7052

    Article  PubMed  CAS  Google Scholar 

  22. Daly CJ, McGrath JC (2011) Previously unsuspected widespread cellular and tissue distribution of β-adrenoceptors and its relevance to drug action. Trends Pharmacol Sci 32:219–226

    Article  PubMed  CAS  Google Scholar 

  23. Jansen L, Below J, Chang-Claude J et al (2012) Beta blocker use and colorectal cancer risk: population-based case–control study. Cancer 118(16):3911–3919

    Article  PubMed  CAS  Google Scholar 

  24. Sørensen GV, Ganz PA, Cole SW et al (2013) Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study. J Clin Oncol 31(18):2265–2272

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy

    Edoardo Botteri, Nicole Rotmensz, Barbara Santillo & Sara Gandini

  2. Division of Medical Senology, European Institute of Oncology, Milan, Italy

    Elisabetta Munzone & Marco Colleoni

  3. Division of Cardiology, European Institute of Oncology, Milan, Italy

    Carlo Cipolla & Arnaldo Zanelotti

  4. Department of Dermatology, University of Florence, Florence, Italy

    Vincenzo De Giorgi

  5. Department of Medicine, European Institute of Oncology, Milan, Italy

    Laura Adamoli & Aron Goldhirsch

  6. Department of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy

    Giuseppe Viale

  7. University of Milan, Milan, Italy

    Giuseppe Viale

Authors
  1. Edoardo Botteri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elisabetta Munzone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nicole Rotmensz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carlo Cipolla
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vincenzo De Giorgi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Barbara Santillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Arnaldo Zanelotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Laura Adamoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Marco Colleoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Giuseppe Viale
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Aron Goldhirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Sara Gandini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edoardo Botteri.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material (PDF 8 kb)

Supplementary material (DOC 29 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Botteri, E., Munzone, E., Rotmensz, N. et al. Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Res Treat 140, 567–575 (2013). https://doi.org/10.1007/s10549-013-2654-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-013-2654-3

Keywords

Search

Navigation